ACIP Presentation Slides: February 28-29, 2024 Meeting

Note: These files are not yet 508

Slides will be added as they become available.

February 28, 2024

Welcome & Introductions

• Introduction
  Dr. M Wharton
  

COVID-19 Vaccines

• Introduction [7 pages]
  Dr. M Daley
• COVID-19-associated hospitalizations among adults – COVID-NET [13 pages]
  Dr. C Taylor
• COVID-19 vaccination coverage update [27 pages]
  Dr. K Chatham-Stephens
• COVID-19 vaccine effectiveness [21 pages]
  Dr. R Link-Gelles
• Economic analysis of an additional dose of COVID-19 vaccine [24 pages]
  Dr. L Prosser
• Evidence to Recommendations [81 pages]
  Dr. M Wallace
• Next steps for the COVID-19 vaccine program [18 pages]
  Dr. L Panagiotakopoulos

Chikungunya Vaccines

• Introduction [7 pages]
  Dr. W Chen
• Update on chikungunya vaccine licensure [6 pages]
  Dr. S Hills
• Review of proposed policy options for chikungunya vaccine use among U.S. adults traveling abroad [28 pages]
  Dr. S Hills
• Review of proposed policy options for chikungunya vaccine use among laboratory workers [7 pages]
  Dr. S Hills
• Vaccine use among pregnant and breastfeeding women [28 pages]
  Dr. S Hills, Dr. D Meaney-Delman

DT Vaccine

• Guidance to use Td vaccine for those instances when receipt of the pertussis component is contraindicated [19 pages]
  Dr. M Hughes, Dr. J Santoli

Influenza Vaccines

• Introduction [7 pages]
  Dr. J Loehr
• Interim Estimates of 2023–24 Seasonal Influenza Vaccine Effectiveness [37 pages]
  Dr. A Frutos
• Interim Influenza Vaccine Effectiveness Against Laboratory-Confirmed Influenza in California, October 2023—January 2024 [15 pages]
  Dr. S Zhu
• Safety of LAIV4 in Children with Asthma [18 pages]
  Dr. B Creech
• Influenza B/Yamagata Update [3 pages]
  Dr. L Grohskopf

Polio Vaccines

• Introduction [2 pages]
  Dr. O Brooks
• Considerations for the Potential Use of Novel Type 2 Oral Poliovirus Vaccine (nOPV2) as an Outbreak Control Measure in the United States [41 pages]
  Dr. S Kidd
• Clinical considerations for children who received fractional dose inactivated polio vaccine (fIPV) in other countries [18 pages]
  Dr. S Kidd

February 29, 2024

Welcome & Introductions

• Introduction
  Dr. M Wharton

Respiratory syncytial virus (RSV) Vaccines Adults

• Introduction [10 pages]
  Dr. C Kotton
• Manufacturer presentation: Moderna safety & efficacy in adults aged ≥60 years [48 pages]
  Dr. R Das
• Risk-stratified rates of RSV-associated hospitalization among adults [26 pages]
  Dr. R Woodruff
• Implementation update: older adult RSV vaccination [30 pages]
  Dr. C Black
• Post-marketing safety surveillance of older adult RSV vaccination [34 pages]
  Dr. T Shimabukuro
• Preliminary Analysis of Guillain-Barré Syndrome (GBS) following RSV Vaccination among adults 65 years and older [11 pages]
  Dr. P Lloyd
• Older adult RSV vaccination: benefits and risks discussion [33 pages]
  Dr. M Melgar
• Work group interpretations and discussion [41 pages]
  Dr. A Britton

Meningococcal Vaccines

• Introduction [6 pages]
  Dr. J Loehr
• Revising the Adolescent Meningococcal Vaccine Schedule: Term of Reference and Considerations [24 pages]
  Dr. S Schillie
• GSK Pentavalent MenABCWY vaccine: Term of Reference [10 pages]
  Dr. S Schillie

Pneumococcal Vaccines

• Introduction [12 pages]
  Dr. J Loehr
• Current epidemiology of invasive pneumococcal disease and pneumococcal vaccine coverage in adults [35 pages]
  Mr. R Gierke
• Preliminary findings of the Pneumococcal pNeumonia Epidemiology, Urine serotyping, and Mental Outcomes (PNEUMO) US study [14 pages]
  Dr. W Self
• Phase 3 clinical trial data of PCV21 [37 pages]
  Dr. H Platt
• Post-licensure PCV20 safety data [19 pages]
  Dr. P Moro
• Safety Assessment of PCV20 [16 pages]
  Dr. R Forshee
• PCV21 Policy Questions and Preliminary WG interpretations of EtR [57 pages]
  Dr. M Kobayashi

Combined Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus influenzae Type B Conjugate, and Hepatitis B vaccine (Vaxelis®)

• Introduction [7 pages]
  Dr. J Loehr
• Background on invasive Hib disease and vaccination among American Indian and Alaska Native Populations [38 pages]
  Dr. J Collins
• The HibVax Study: Immunogenicity of H. influenzae type b PRP-OMP vaccines in American Indian and Alaska Native infants [29 pages]
  Dr. L Hammitt
• Work group considerations [13 pages]
  Dr. J Collins